TQB2450

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerLung CancerSmall Cell Lung CancerEsophageal Squamous Cell CarcinomaPaclitaxelAdvanced Renal Cancer

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Ensacove

XXcovery Holdings, Inc.

Phase 3

82

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 3

23

TQB2450

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

64

Firmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

25

Remeron

OOrganon and Co

Preclinical

16

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—7

Treatment

GSK

Preclinical

18

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

2Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer6 trials

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT03910127·90 enrolled

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06109402·160 enrolled

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04964479·375 enrolled

Show 3 more trials

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05718167·570 enrolled

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04325763·315 enrolled

A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04306926·59 enrolled

Small Cell Lung Cancer3 trials

A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Unknown status·JJinming Yu·Phase 1·NCT05942508·20 enrolled

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05913089·58 enrolled

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04234607·738 enrolled

Anlotinib2 trials

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT04236362·90 enrolled

Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Unknown status·—·Phase 3·NCT04665609·80 enrolled

Breast Cancer2 trials

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT03855358·30 enrolled

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04405505·332 enrolled

Lymphoma2 trials

A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT03800706·85 enrolled

Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Terminated·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04002622·1 enrolled

16 more indications

Lung Cancer2 trials

PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT04539977·40 enrolled

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT03983928·30 enrolled

Endometrial Cancer2 trials

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Terminated·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05481645·71 enrolled

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer

Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04574284·170 enrolled

Patients With Advanced Solid Tumors2 trials

A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT06116240·135 enrolled

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT03897283·22 enrolled

Adenocarcinoma1 trial

Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes

Unknown status·HHenan Cancer Hospital·Phase 1/2·NCT05608785·45 enrolled

Advanced Renal Cancer1 trial

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04523272·528 enrolled

Cholangiocarcinoma1 trial

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT03996408·42 enrolled

Melanoma1 trial

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT03991975·42 enrolled

Nasopharyngeal Carcinoma1 trial

A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma

Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04895345·25 enrolled

Paclitaxel1 trial

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Not yet recruiting·PPeking University·Phase 2·NCT06222944·90 enrolled

Second-line Treatment1 trial

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04809142·392 enrolled

Ovarian Cancer1 trial

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05145218·405 enrolled

Hepatocellular Carcinoma1 trial

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1/2·NCT03825705·60 enrolled

Adjuvant Therapy1 trial

TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

Unknown status·XXianhai Mao·Phase 2·NCT05111366·37 enrolled

Esophageal Squamous Cell Carcinoma1 trial

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

Recruiting·JJiangxi Provincial Cancer Hospital·Phase 2·NCT05252078·30 enrolled

Tolerance1 trial

Tolerance and Pharmacokinetics of TQB2450

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT03460457·50 enrolled

Cervical Cancer1 trial

A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer

Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04623333·80 enrolled

Details

Drug Info

Related News